Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
Amgen's tarlatamab combined with AstraZeneca's durvalumab extended median overall survival to 21.1 months in ES-SCLC patients, vs 12-13 months with standard therapy, per phase 3 trial results. The study showed a 58% reduction in death risk. Both companies plan regulatory filings.
How this was made
The 30-second read
Why it matters
The data provide a strong basis for regulatory filings and could materially affect the market valuations of both Amgen and AstraZeneca.
Market read
First‑report of pivotal trial data likely triggers price moves in Amgen and AstraZeneca as investors price in a new indication.
What to watch
Long‑term OS data and comparative efficacy versus lurbinectedin‑atezolizumab remain unknown.
Background
Interim results from the global phase‑3 DeLLphi‑305 trial were presented at ESMO 2026 and published in NEJM, showing a 58% reduction in risk of death for the tarlatamab‑durvalumab combo.
Ticker impact
Amgen announced interim phase‑3 data showing tarlatamab‑durvalumab improves median OS to 21.1 months versus durvalumab alone.
upward pressure as market prices in potential label expansion and revenue uplift.
Phase‑3 OS benefit (HR 0.42, p < 0.001) is material; Amgen has a clear path to filing, driving near‑term upside.
AstraZeneca’s durvalumab combined with Amgen’s tarlatamab showed a large survival benefit in ES‑SCLC interim results.
upward pressure as investors value the expanded use of Imfinzi in first‑line maintenance.
Durvalumab’s contribution to a significant OS gain positions AstraZeneca for potential co‑marketing and increased sales.
Market effects
Strengthens the ES‑SCLC immunotherapy segment and may boost related biotech stocks.
Positive for US biotech market; could influence European oncology peers.
Highlights a potential new standard of care in extensive‑stage small‑cell lung cancer worldwide.
Counterpoint
If regulatory scrutiny on trial design or safety concerns (CRS, ICANS) intensifies, the upside could be limited.
Key entities
- CompanyAmgen
Biotech firm developing tarlatamab.
- CompanyAstraZeneca
Pharma company marketing durvalumab (Imfinzi).
